Stock GENOMIC HEALTH, INC.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

News Genomic Health, Inc.

Equities

US37244C1018

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
MDxHealth SA acquired Oncotype DX GPS Prostate Cancer Business from Genomic Health, Inc. for approximately $100 million.
CI
Biocartis Group NV and Biocartis and Genomic Health, Inc. Agree to End Collaboration Due to Changed Market Circumstances
CI
Genomic Health, Inc. Announces Executive Changes
CI
Genomic Health, Inc.(NasdaqGS:GHDX) dropped from S&P 1000
CI
Genomic Health, Inc.(NasdaqGS:GHDX) dropped from S&P 600 Health Care
CI
Genomic Health, Inc.(NasdaqGS:GHDX) dropped from S&P 600
CI
Genomic Health, Inc.(NasdaqGS:GHDX) dropped from S&P Global BMI Index
CI
Genomic Health, Inc.(NasdaqGS:GHDX) dropped from S&P Composite 1500
CI
Genomic Health, Inc.(NasdaqGS:GHDX) dropped from S&P TMI Index
CI
Genomic Health, Inc.(NasdaqGS:GHDX) dropped from S&P Biotechnology Select Industry Index
CI
Genomic Health, Inc.(NasdaqGM:GHDX) dropped from NASDAQ Composite Index
CI
Exact Sciences Corporation completed the acquisition of Exact Sciences Corporation from Baker Bros. Advisors LP and others.
CI
Genomic Health : Stockholders Approve Proposed Acquisition by Exact Sciences
PR
Genomic Health, Inc.(NasdaqGS:GHDX) dropped from NASDAQ Biotechnology Index
CI
Genomic Health Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019
CI
Genomic Health : New TAILORx Data, Published Today in JAMA Oncology, Add to Strong Evidence Base Reinforcing Unique Ability of Oncotype DX Breast Recurrence Score® Test to Guide Chemotherapy Treatment
PR
Genomic Health, Inc. Announces Results from a New Analysis of the Trial Assigning IndividuaLised Options for Treatment (Rx), or TAILORx
CI
Genomic Health : New St. Gallen International Breast Cancer Guidelines Recommend Oncotype DX Breast Recurrence Score® Test to Guide Chemotherapy for Node-negative and Node-positive Early-stage Breast Cancer
PR
New St. Gallen International Breast Cancer Guidelines Recommends Oncotype DX Breast Recurrence Score® Test to Guide Chemotherapy for Node-negative and Node-positive Early-stage Breast Cancer
CI
WeissLaw LLP Investigates Genomic Health, Inc.
PR
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. Stock
  4. News Genomic Health, Inc.